PFE Pfizer Inc.
Price (delayed)
$34.51
Market cap
$191.7B
P/E Ratio
12.15
Dividend/share
$1.48
EPS
$2.84
Enterprise value
$241.83B
Business Summary
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.pfizer.com
Highlights
The price to earnings (P/E) is 40% lower than the 5-year quarterly average of 20.1 and 13% lower than the last 4 quarters average of 14.0
Pfizer Inc's equity has increased by 11% YoY and by 3% QoQ
Pfizer Inc's EPS has increased by 43% YoY but it has decreased by 2.7% from the previous quarter
Pfizer Inc's net income has increased by 38% YoY but it has decreased by 3% QoQ
Pfizer Inc's revenue has decreased by 6% YoY and by 2.1% QoQ
Pfizer Inc's gross profit has decreased by 5% YoY and by 2.5% from the previous quarter
Key stats
Shares outstanding
5.55B
Market cap
$191.7B
Enterprise value
$241.83B
EBIT
$17.22B
EBITDA
$22.9B
Price to earnings (P/E)
12.15
Price to book (P/B)
2.94
Price to sales (P/S)
3.78
EV/EBIT
14.05
EV/EBITDA
10.56
Net debt/EBITDA
2.19
EV/Sales
4.77
EBITDA margin
45.2%
Gross margin
79.9%
Net margin
31.2%
Operating margin
18.1%
Return on assets
9.6%
Return on equity
25%
Return on invested capital
20%
Return on capital employed
13%
Return on sales
34%
Debt to equity
0.8
Free cash flow
$11.55B
Free cash flow per share
$2.08
Book value per share
$11.72
Revenue per share
$9.14
TBVPS
$13.23
Current ratio
1.03
Quick ratio
0.6
Working capital
$848M
Dividend yield
4.29%
DPS
$1.48
Payout ratio
52.1%
PFE stock price
Financial performance
PFE's net margin is up by 47% YoY
Pfizer Inc's net income has increased by 38% YoY but it has decreased by 3% QoQ
The operating income has contracted by 24% YoY and by 4.7% from the previous quarter
The company's operating margin fell by 19% YoY and by 2.2% QoQ
Valuation
Price to earnings (P/E)
Price to book (P/B)
Price to sales (P/S)
Current price to earnings (P/E):
12.15
Pfizer Inc's EPS has increased by 43% YoY but it has decreased by 2.7% from the previous quarter
The price to earnings (P/E) is 40% lower than the 5-year quarterly average of 20.1 and 13% lower than the last 4 quarters average of 14.0
Current price to book (P/B):
2.94
PFE's P/B is 11% below its 5-year quarterly average of 3.3 and 11% below its last 4 quarters average of 3.3
Pfizer Inc's equity has increased by 11% YoY and by 3% QoQ
Current price to sales (P/S):
3.78
PFE's P/S is 8% below its 5-year quarterly average of 4.1 and 6% below its last 4 quarters average of 4.0
Pfizer Inc's revenue has decreased by 6% YoY and by 2.1% QoQ
Efficiency
Pfizer Inc's ROS has soared by 52% YoY
The ROE rose by 44% YoY but it fell by 5% QoQ
Pfizer Inc's ROA has increased by 35% YoY but it has decreased by 4% from the previous quarter
The company's return on invested capital rose by 27% YoY but it fell by 4.8% QoQ
Dividends
DPS
$1.48
Dividend yield
4.29%
Payout ratio
52.1%
Recent dividends
Financial health
Assets vs liabilities
PFE's total assets is 65% greater than its total liabilities
The current ratio has contracted by 33% YoY but it has grown by 17% from the previous quarter
The quick ratio has grown by 20% from the previous quarter but it has contracted by 17% YoY
Debt vs equity
PFE's debt is 20% less than its equity
Pfizer Inc's equity has increased by 11% YoY and by 3% QoQ
The debt to equity has grown by 3.9% YoY but it has contracted by 3.6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.